GHRP-2 Peptide UK Guide: Pralmorelin Research and Study Data

Most research peptides never make it out of the laboratory. They accumulate preclinical data, appear in a few dozen papers, and remain compounds rather than medicines.

GHRP-2 is the exception. Under the name pralmorelin, it was approved in Japan as a diagnostic agent for growth hormone deficiency and marketed by Kaken Pharmaceutical as GHRP Kaken 100. It was the first growth hormone secretagogue of its class to be introduced clinically anywhere in the world.

That regulatory history makes it unusual among research peptides, and it means the pharmacology has been characterised to a standard most compounds in this space never reach. If you want a growth hormone secretagogue whose dose-response behaviour is genuinely well documented, this is it.

GHRP-2 is supplied as a research compound for laboratory use only — not a medicine, not approved for human consumption in the UK, and not sold for any clinical purpose.

What GHRP-2 Actually Is

GHRP-2 is a synthetic hexapeptide — six amino acids — with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂ and a molecular weight of approximately 817.9 Da.

Look closely at that sequence and something stands out: three of the six residues are in the D configuration. Naturally occurring amino acids are almost universally L-form, and proteolytic enzymes evolved to recognise and cleave L-form sequences. Building a peptide with D-amino acids at three positions presents those enzymes with a substrate they handle poorly.

There is also a non-standard residue: D-2-naphthylalanine, an amino acid with a bulky bicyclic aromatic side chain not found in natural proteins at all.

Structurally, GHRP-2 is described as an analogue of met-enkephalin — one of the body’s endogenous opioid peptides. That origin is a historical curiosity rather than a functional one; the compound acts on an entirely different receptor.

It carries a number of names across the literature, which can make searching confusing: pralmorelin, pralmorelin hydrochloride, pralmorelin dihydrochloride, growth hormone-releasing peptide 2, and the development codes KP-102, GPA-748 and WAY-GPA-748.

The Line That Runs Back to 1984

The growth hormone-releasing peptides did not emerge from a screening programme. They came from a single observation that took more than a decade to explain.

Cyrus Bowers and colleagues published work in Endocrinology in 1984 describing peptides that stimulated growth hormone secretion through a mechanism clearly distinct from growth hormone-releasing hormone. Further work followed in 1989. The effect was reproducible and the pathway was unknown.

That is an uncomfortable position for drug development. You have compounds that work, no receptor to characterise, and no natural ligand to compare them against. The standard tools of pharmacology — binding assays, competition studies, structure-activity relationships anchored to an endogenous hormone — were largely unavailable.

What the researchers could do was optimise empirically. Test sequences, measure growth hormone response, keep what worked. GHRP-2’s unusual composition — three D-amino acids and a synthetic naphthylalanine residue — is the product of that process. Each modification earned its place by producing a measurable improvement in stability or potency, not by fitting a structural model of a receptor nobody had found.

The receptor arrived in 1996. Ghrelin arrived in 1999. By then GHRP-2 was already heading toward regulatory approval in Japan.

There is a lesson in that sequence worth noting, because it runs against how drug discovery is usually described. The mechanism-first narrative — identify target, design ligand, optimise — is the modern ideal. This class was built the other way round, and produced a compound clinically validated enough to become a diagnostic standard.

The Receptor It Was Built Before Anyone Found

Here is the part of the story that makes GHRP-2 genuinely interesting from a drug discovery perspective.

The growth hormone-releasing peptides were developed by researchers at Polygen in Germany and Tulane University in the United States, building on work stretching back to the early 1980s. They knew these compounds stimulated growth hormone release. They knew it happened through a mechanism different from growth hormone-releasing hormone, the established pathway.

What they did not know was what the compounds were binding to.

The receptor — the growth hormone secretagogue receptor, or GHSR — was not identified until 1996, published in Science by Howard and colleagues. The peptides that activate it had been in development for over a decade by then.

And then in 1999 the natural ligand was found: ghrelin, a 28-amino-acid peptide bearing an octanoyl modification, first isolated from the stomach. The synthetic compounds had been mimicking a hormone nobody had discovered yet.

That sequence of events — drug first, receptor second, natural hormone third — is unusual in pharmacology and worth appreciating. GHRP-2 is a synthetic ghrelin analogue that predates the discovery of ghrelin.

Where the receptor is found

GHSR is a G-protein coupled receptor with seven transmembrane domains, and the pituitary form is designated GHSR1a. Critically, it is distinct from the growth hormone-releasing hormone receptor — two separate receptors, two separate pathways, both converging on growth hormone release.

The receptor is expressed in the pituitary and hypothalamus, where its role in growth hormone secretion is obvious. But it has also been detected across the central nervous system and in a range of peripheral tissues: adrenal and thyroid glands, heart, lung, kidney and skeletal muscle.

That distribution matters for research. A compound acting at GHSR is not acting on one tissue — which opens research questions well beyond growth hormone, and explains some of the more unexpected findings discussed below.

Why Pulsatile Release Changes Everything

To understand why secretagogues are studied at all, rather than simply using growth hormone itself, you need to know how the hormone is naturally released.

Growth hormone is not secreted continuously. It comes in pulses — bursts separated by periods of near-silence, with the largest pulses occurring during deep sleep. Between bursts, circulating levels can be close to undetectable.

That pattern is not incidental. Target tissues respond differently to pulsatile exposure than to constant exposure, and receptor sensitivity is maintained partly by the gaps. Continuous elevation tends to produce downregulation, where the same concentration achieves progressively less.

Administering growth hormone directly overrides the pattern. It produces sustained elevation rather than pulses, which is a fundamentally different signal from the one the system evolved to interpret.

A secretagogue works differently. It prompts the pituitary to release its own stored hormone, which means the release retains a pulse-like character and remains subject to the body’s own regulatory feedback. Somatostatin — the hormone that opposes growth hormone release — still operates. The pituitary’s storage capacity still sets a ceiling.

For research purposes that distinction is the entire point. Studying a secretagogue is studying the regulatory system. Studying exogenous hormone is bypassing it.

It also explains why the diagnostic application works. A test that measures the pituitary’s capacity to respond tells you something about pituitary function. Measuring circulating hormone after direct administration would tell you only that you had administered it.

GHRP-2 Research Peptide

HPLC and MS verified · batch certificate published · dispatched from the UK before 2pm

from£20.99View GHRP-2 Research Peptide

How It Works

GHRP-2 binds GHSR1a on pituitary somatotrophs — the cells that produce and store growth hormone — and triggers release.

Because it works through a separate receptor from growth hormone-releasing hormone, the two pathways can be studied independently or in combination, and their effects are not simply additive in the way two agonists at the same receptor would be. This is the pharmacological basis for protocols pairing a secretagogue with a GHRH analogue.

The characteristic that made GHRP-2 clinically useful is the reliability of the response. Acute administration markedly increases plasma growth hormone in healthy subjects irrespective of gender, obesity or age. That consistency is rare and it is precisely what a diagnostic test requires.

It also reliably induces sensations of hunger and increases food intake in humans — unsurprising given that it is a ghrelin analogue, and ghrelin is the hormone most associated with appetite signalling.

The Diagnostic Application

The approval in Japan rests on a straightforward and rather elegant principle.

In healthy subjects, GHRP-2 produces a large growth hormone response.

In patients with growth hormone deficiency, the response is significantly lower.

That difference is the test. Administer a standardised quantity, measure the growth hormone response, and the magnitude distinguishes intact pituitary function from deficiency. A Japanese multi-centre randomised trial established the threshold, with pralmorelin at 1 microgram per kilogram intravenously producing a growth hormone response above 15 micrograms per litre in healthy subjects and below that figure in severe deficiency — validating the diagnostic cutoff. The review documenting this development programme is indexed on PubMed under PMID 15230633.

Kaken Pharmaceutical released the diagnostic kit onto the Japanese market with approval for intravenous administration, and retains rights to pralmorelin in Japan. A separate programme, designated KP-102 LN, took the compound into Phase II trials for short stature.

Worth stating clearly: this approval is specific to Japan and specific to diagnostic use. It is not a UK licence and not a treatment indication.

The Oral Bioavailability Problem

One limitation shaped the entire subsequent history of this drug class, and it is worth understanding.

The peptidyl growth hormone secretagogues have oral bioavailability generally accepted as below 1%. Swallow them and almost nothing reaches circulation intact — the digestive tract treats them as food, which is precisely what a peptide is.

Some literature describes GHRP-2 as orally active, and both statements can be true: activity by that route is demonstrable but the fraction absorbed is very small, which is why the approved diagnostic formulation is intravenous.

That constraint drove a substantial research effort to find non-peptide compounds mimicking the same receptor activity. Benzolactams and spiroindanes were investigated, and the best-known result was MK-0677 — a small molecule GHSR agonist with the oral properties the peptides lacked.

So GHRP-2 occupies an interesting position: clinically validated, well characterised, and superseded for oral applications by molecules designed specifically to overcome its principal weakness.

The Research Nobody Expects

Because GHSR appears in tissues well beyond the pituitary, GHRP-2 has been studied in contexts that have nothing to do with growth hormone.

One example, published in the International Journal of Molecular Sciences and indexed under PMC5000754, examined GHRP-2 in human ovarian granulosa cells. The researchers activated protein kinase C with a phorbol ester to induce an inflammatory response, then tested whether GHRP-2 modified it.

The endpoints were inflammatory mediators — cyclooxygenase-2, prostaglandin E₂ and interleukin-8. The study confirmed the presence of GHRP-2’s cognate receptors in these cells by RT-PCR before testing, and examined the signalling mechanisms through which GHRP-2 influenced their production.

The authors also noted a practical reason GHRP-2 is used in place of ghrelin itself: ghrelin has a short half-life, so the synthetic analogue has been extensively used across many studies as a more tractable tool.

That is the broader point. GHRP-2 is not only a growth hormone research compound. It is a stable, well-characterised ghrelin receptor agonist, which makes it useful wherever GHSR signalling is the question — and GHSR turns up in more places than anyone initially expected.

How GHRP-2 Compares Within Its Class

Several compounds share this mechanism, and the differences between them are practical rather than academic.

GHRP-6 was the earlier compound and the reference point for the whole class — the search for non-peptide alternatives was explicitly framed as finding molecules that mimicked GHRP-6’s action in the pituitary. It is associated with more pronounced appetite stimulation than GHRP-2. Both are available as research material: GHRP-2 and GHRP-6.

Ipamorelin is the selectivity story. It is a GHSR agonist like the others but with a cleaner profile, showing less effect on the other hormones that GHRPs can influence. Where attributing an effect specifically to growth hormone matters, Ipamorelin is often the better-controlled choice.

Hexarelin is the fourth member commonly grouped with GHRP-1, GHRP-2 and GHRP-6 in the literature as the synthetic growth hormone secretagogues.

And then there is the other pathway entirely. Sermorelin, CJC-1295 with DAC and Tesamorelin are GHRH analogues — acting at the growth hormone-releasing hormone receptor rather than GHSR. Because the two receptors are distinct, combination protocols are pharmacologically coherent rather than redundant, which is the reasoning behind the CJC-1295 and Ipamorelin combination.

Related Compounds Worth Studying Alongside

Beyond its own class, GHRP-2 connects to several research areas.

Metabolic compounds. Since ghrelin signalling sits at the intersection of growth hormone and energy balance, MOTS-c, 5-Amino-1MQ and AOD-9604 appear in adjacent research. AOD-9604 is a particularly interesting comparator: it is a fragment of growth hormone itself, isolating one function of the hormone that GHRP-2 causes to be released.

Tissue repair. Growth hormone research overlaps with recovery and repair questions, where BPC-157 and TB-500 are studied, along with the Wolverine Stack combining both.

Inflammatory signalling. Given the granulosa cell findings, compounds studied in inflammatory contexts are natural comparators — KPV and Thymosin Alpha-1 among them.

Longevity compounds. Epitalon and NAD+ approach age-related research through unrelated mechanisms, making them useful contrasts in study design.

Designing Research With GHRP-2

Several practical considerations follow from the pharmacology, and most of them concern controlling for things the compound does beyond its headline effect.

Account for the appetite effect. GHRP-2 reliably increases food intake. In any animal model where body composition, metabolic rate or energy balance is an endpoint, that is a confounding variable rather than a side note — an observed change may originate in altered intake rather than in growth hormone signalling. Controlling intake, or measuring it, separates the two.

Time the sampling to the pulse. Because release is pulsatile and the response to acute administration is relatively rapid, a single sample taken at the wrong moment can miss the peak entirely. Serial sampling across a defined window captures the response curve rather than a point on it.

Consider the receptor distribution. GHSR is expressed in adrenal and thyroid glands, heart, lung, kidney and skeletal muscle as well as the pituitary. An effect observed in one tissue may originate in another, and attributing a systemic change to pituitary signalling requires ruling out direct peripheral action.

Use the right comparator. If the question concerns GHSR signalling specifically, Ipamorelin’s cleaner selectivity profile makes it a better control than another GHRP. If the question concerns growth hormone release irrespective of route, a GHRH analogue is the more informative comparison because it reaches the same endpoint through a different receptor.

Watch for desensitisation in extended protocols. GHSR is a G-protein coupled receptor, and sustained agonist exposure at GPCRs generally produces internalisation and reduced responsiveness. A declining response over a long protocol may reflect receptor adaptation rather than compound degradation — and distinguishing the two requires re-analysing the stock solution, not simply assuming.

Remember the ghrelin half-life advantage. The reason GHRP-2 is used in place of ghrelin across many studies is that ghrelin degrades rapidly. If the research question is specifically about endogenous ghrelin signalling, the synthetic analogue is a proxy — a good one, but a proxy.

Why Verification Matters for This Sequence

GHRP-2 presents analytical challenges that make batch-specific verification genuinely consequential rather than a formality.

The D-amino acids are invisible to mass spectrometry. Three residues in this sequence are D-configured, and a D-to-L substitution produces a molecule of identical molecular weight. Mass spectrometry will report a clean match. Only chromatographic separation, or specialised enantiomeric analysis, distinguishes the correct compound from a stereochemical impurity — and since the D-configuration is what confers enzymatic resistance, getting it wrong produces a peptide that degrades far faster than it should.

D-2-naphthylalanine is a non-standard residue. It is not a commodity amino acid, and its incorporation is a step where synthesis can fail. Substitution with a standard aromatic residue such as phenylalanine would alter the mass detectably, but it is a specific thing to check.

C-terminal amidation is functionally required. The sequence terminates in an amide rather than a free acid. Failed amidation shifts the mass by about 1 Da — a small difference, detectable only with adequate instrument precision, which is one reason mass accuracy specifications matter on a certificate.

Tryptophan oxidises. The sequence contains tryptophan, among the more oxidation-prone residues. Oxidation adds 16 Da and is a common finding in poorly stored material.

Every batch Crown Peptides supplies carries its own certificate rather than a figure carried forward from an earlier run. Purity is measured by high-performance liquid chromatography, separating the target compound from related substances. Identity is confirmed independently by mass spectrometry.

The batch number on the vial matches the number on the certificate. Read any published certificate through the lab reports library, or scan the QR code on the vial. Guidance on reading the document itself is in the certificate of analysis guide.

Handling and Storage

The tryptophan residue drives most of the storage considerations.

Store lyophilised at −20°C, protected from light. Tryptophan is susceptible to photo-oxidation as well as ordinary oxidation, so light exclusion matters more for this sequence than for many.

Bring to room temperature before opening. A cold vial opened into humid air condenses moisture onto the cake, and lyophilised peptide absorbs it readily.

Reconstitute down the vial wall, then swirl gently. Never shake — foaming creates an air-liquid interface that denatures peptides and increases oxygen exposure.

Keep reconstituted solution refrigerated and use within a defined window. Aliquot before freezing if freezing is necessary.

Because GHRP-2 is typically studied at microgram quantities from milligram vials, the peptide calculator is worth using rather than working the conversions by hand — mg-to-mcg errors are the most common source of quantitative mistakes in this compound class, and the dosage calculation guide covers them. Full storage guidance is in the storage information guide.

Frequently Asked Questions

What is GHRP-2?

A synthetic hexapeptide with the sequence D-Ala-D-2-Nal-Ala-Trp-D-Phe-Lys-NH₂, molecular weight approximately 817.9 Da, acting as an agonist at the ghrelin receptor GHSR1a. It is also known as pralmorelin.

Is GHRP-2 an approved drug?

In Japan, yes — as pralmorelin, marketed by Kaken Pharmaceutical under the brand GHRP Kaken 100, approved as a single-dose diagnostic agent for assessing growth hormone deficiency. That approval is specific to Japan and to diagnostic use. It is not approved in the UK.

What is the difference between GHRP-2 and GHRP-6?

Both are GHSR agonists. GHRP-6 came first and served as the reference compound for the class. GHRP-2 is associated with a stronger growth hormone response and less pronounced appetite stimulation than GHRP-6.

How does GHRP-2 differ from Sermorelin or CJC-1295?

Different receptors entirely. GHRP-2 acts at the growth hormone secretagogue receptor. Sermorelin and CJC-1295 are GHRH analogues acting at the growth hormone-releasing hormone receptor. The two receptors are distinct, which is why combination protocols are pharmacologically coherent.

What is the relationship between GHRP-2 and ghrelin?

GHRP-2 is a synthetic ghrelin analogue — though it was developed before ghrelin was discovered in 1999. Ghrelin is a 28-amino-acid octanoylated peptide and the natural ligand for the same receptor. Because ghrelin has a short half-life, GHRP-2 is often used in its place as a research tool.

Why is GHRP-2 given intravenously in the diagnostic test?

Oral bioavailability for peptidyl growth hormone secretagogues is generally accepted as below 1%. The approved formulation is intravenous because that is the route which delivers a reliable, reproducible response.

Does GHRP-2 affect appetite?

Yes. Acute administration reliably induces sensations of hunger and increases food intake in humans, which follows from its action as a ghrelin receptor agonist. The effect is described as less pronounced than with GHRP-6.

Why do the D-amino acids matter for verification?

A D-to-L substitution produces an identical molecular weight, so mass spectrometry cannot detect it. Since the D-configuration is what gives the peptide resistance to enzymatic degradation, an undetected substitution produces a compound that appears correct and degrades far faster than expected.

What purity should GHRP-2 be supplied at?

≥98% for analytical work, confirmed by HPLC with identity verified by mass spectrometry against a batch-specific certificate. The chromatogram carries particular weight here because of the stereochemistry mass spectrometry cannot see.

The Most Documented Compound in Its Class

What sets GHRP-2 apart is not potency or novelty. It is evidence.

This is a compound with completed Phase II and Phase III trials, a regulatory approval in a major market, a validated diagnostic threshold, and a documented dose-response relationship that holds across gender, age and body composition. Very few research peptides can claim any of that, and almost none can claim all of it.

It also carries a genuinely odd history — a synthetic analogue of a hormone that had not been discovered, acting at a receptor that had not been identified, developed on the strength of an observed effect nobody could yet explain. The drug arrived first and the biology caught up.

And the biology is still catching up. GHSR turns out to be expressed across the central nervous system and in adrenal, thyroid, cardiac, pulmonary, renal and skeletal muscle tissue. Work such as the granulosa cell inflammation study suggests the research questions extend considerably beyond the pituitary.

GHRP-2 is available as research-grade material, HPLC and mass spectrometry verified, with the full certificate published against every batch number. Browse the wider research peptide range for related compounds.